|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Medical Centre Leeuwarden |
|---|---|
| Information provided by: | Medical Centre Leeuwarden |
| ClinicalTrials.gov Identifier: | NCT00298454 |
Purpose
Intensive care patients with multiple organ dysfunction syndrome often show renal failure with the need for hemofiltration. Resolving renal failure after cessation of hemofiltration may or may not be accompanied by oliguria. Whether or not the administration of diuretics at that moment is appropriate is not known. The study randomises between furosemide or placebo when hemofiltration is stopped. Study endpoint is recovery of renal function.
| Condition | Intervention | Phase |
|---|---|---|
|
Renal Failure Critically Ill |
Drug: Furosemide |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Forced Diuresis Vs Observation in Resolving Renal Failure After Haemofiltration in Critically Ill Patients (Fodorefh) |
| Estimated Enrollment: | 72 |
| Study Start Date: | December 2005 |
| Study Completion Date: | April 2007 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Netherlands | |
| Dept of intensive care, Medical Centre Leeuwarden | |
| Leeuwarden, Fr, Netherlands, 8901 BR | |
| Principal Investigator: | Peter van der Voort, MD, PhD, MSc | Dept of intensive care, Medical Centre Leeuwarden, PO Box 888,8901BR Leeuwarden, The Netherlands |
More Information
| ClinicalTrials.gov Identifier: | NCT00298454 History of Changes |
| Other Study ID Numbers: | 200601 |
| Study First Received: | March 1, 2006 |
| Last Updated: | April 18, 2007 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
|
renal failure oliguric critically ill furosemide |
|
Critical Illness Renal Insufficiency Disease Attributes Pathologic Processes Kidney Diseases Urologic Diseases Furosemide Sodium Potassium Chloride Symporter Inhibitors |
Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Diuretics Natriuretic Agents Physiological Effects of Drugs Cardiovascular Agents Therapeutic Uses |